StreetInsider.com News Articles

Ukraine Ministry of Health Accepts Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway

Wed, 22 Jul 2026 07:45:00 -0400

Government acceptance initiates formal regulatory review of Entolimod under Ukraine's Regulatory Equivalency pathway, with a potential review expected in as few as 45- to 60-days.

Ukraine Ministry of Health Accepts Entolimod for Formal Review — Following its request for submission, Ukraine's Ministry of Health has accepted Valion Bio's Entolimod regulatory dossier for formal review under the country's Regulatory Equivalence Pathway, initiating the Ministry's scientific and regulatory evaluation.
Potential Regulatory Decision Expected in 45–60 Days — Ukraine's FDA-recognition pathway leverages existing U.S. regulatory work and

Ukraine Ministry of Health Accepts Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway

Wed, 22 Jul 2026 07:45:00 -0400

Government acceptance initiates formal regulatory review of Entolimod under Ukraine's Regulatory Equivalency pathway, with a potential review expected in as few as 45- to 60-days.

Ukraine Ministry of Health Accepts Entolimod for Formal Review — Following its request for submission, Ukraine's Ministry of Health has accepted Valion Bio's Entolimod regulatory dossier for formal review under the country's Regulatory Equivalence Pathway, initiating the Ministry's scientific and regulatory evaluation.
Potential Regulatory Decision Expected in 45–60 Days — Ukraine's FDA-recognition pathway leverages existing U.S. regulatory work and

Ukraine Ministry of Health Accepts Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway

Wed, 22 Jul 2026 07:45:00 -0400

Government acceptance initiates formal regulatory review of Entolimod under Ukraine's Regulatory Equivalency pathway, with a potential review expected in as few as 45- to 60-days.

Ukraine Ministry of Health Accepts Entolimod for Formal Review — Following its request for submission, Ukraine's Ministry of Health has accepted Valion Bio's Entolimod regulatory dossier for formal review under the country's Regulatory Equivalence Pathway, initiating the Ministry's scientific and regulatory evaluation.
Potential Regulatory Decision Expected in 45–60 Days — Ukraine's FDA-recognition pathway leverages existing U.S. regulatory work and

Ukraine Ministry of Health Accepts Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway

Wed, 22 Jul 2026 07:45:00 -0400

Government acceptance initiates formal regulatory review of Entolimod under Ukraine's Regulatory Equivalency pathway, with a potential review expected in as few as 45- to 60-days.

Ukraine Ministry of Health Accepts Entolimod for Formal Review — Following its request for submission, Ukraine's Ministry of Health has accepted Valion Bio's Entolimod regulatory dossier for formal review under the country's Regulatory Equivalence Pathway, initiating the Ministry's scientific and regulatory evaluation.
Potential Regulatory Decision Expected in 45–60 Days — Ukraine's FDA-recognition pathway leverages existing U.S. regulatory work and

Ukraine Ministry of Health Accepts Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway

Wed, 22 Jul 2026 07:45:00 -0400

Government acceptance initiates formal regulatory review of Entolimod under Ukraine's Regulatory Equivalency pathway, with a potential review expected in as few as 45- to 60-days.

Ukraine Ministry of Health Accepts Entolimod for Formal Review — Following its request for submission, Ukraine's Ministry of Health has accepted Valion Bio's Entolimod regulatory dossier for formal review under the country's Regulatory Equivalence Pathway, initiating the Ministry's scientific and regulatory evaluation.
Potential Regulatory Decision Expected in 45–60 Days — Ukraine's FDA-recognition pathway leverages existing U.S. regulatory work and

Ukraine Ministry of Health Accepts Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway

Wed, 22 Jul 2026 07:45:00 -0400

Government acceptance initiates formal regulatory review of Entolimod under Ukraine's Regulatory Equivalency pathway, with a potential review expected in as few as 45- to 60-days.

Ukraine Ministry of Health Accepts Entolimod for Formal Review — Following its request for submission, Ukraine's Ministry of Health has accepted Valion Bio's Entolimod regulatory dossier for formal review under the country's Regulatory Equivalence Pathway, initiating the Ministry's scientific and regulatory evaluation.
Potential Regulatory Decision Expected in 45–60 Days — Ukraine's FDA-recognition pathway leverages existing U.S. regulatory work and

Ukraine Ministry of Health Accepts Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway

Wed, 22 Jul 2026 07:45:00 -0400

Government acceptance initiates formal regulatory review of Entolimod under Ukraine's Regulatory Equivalency pathway, with a potential review expected in as few as 45- to 60-days.

Ukraine Ministry of Health Accepts Entolimod for Formal Review — Following its request for submission, Ukraine's Ministry of Health has accepted Valion Bio's Entolimod regulatory dossier for formal review under the country's Regulatory Equivalence Pathway, initiating the Ministry's scientific and regulatory evaluation.
Potential Regulatory Decision Expected in 45–60 Days — Ukraine's FDA-recognition pathway leverages existing U.S. regulatory work and

Ukraine Ministry of Health Accepts Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway

Wed, 22 Jul 2026 07:45:00 -0400

Government acceptance initiates formal regulatory review of Entolimod under Ukraine's Regulatory Equivalency pathway, with a potential review expected in as few as 45- to 60-days.

Ukraine Ministry of Health Accepts Entolimod for Formal Review — Following its request for submission, Ukraine's Ministry of Health has accepted Valion Bio's Entolimod regulatory dossier for formal review under the country's Regulatory Equivalence Pathway, initiating the Ministry's scientific and regulatory evaluation.
Potential Regulatory Decision Expected in 45–60 Days — Ukraine's FDA-recognition pathway leverages existing U.S. regulatory work and

Sheba Medical Center to trial Valion Bio's Entolimod in cancer patients

Mon, 20 Jul 2026 13:30:53 -0400

Valion Bio, Inc. (Nasdaq: VBIO) announced that Sheba Medical Center has finalized a clinical trial protocol to evaluate the company's drug Entolimod in cancer patients receiving high doses of radiation therapy for a rare form of cancer.

Sheba Medical Center, located in Tel Hashomer, Israel, and ranked seventh in Newsweek's 2026 World's Best Hospitals list, approached Valion Bio after identifying Entolimod's potential to reduce radiation-induced neutropenia and protect healthy tissue during radiation treatment. The trial will enroll up to 10 adult patients and will be conducted by Sheba's Benjamin Davidai Department of Radiation Oncology.

Under the agreement, Sheba plans to fund and

World-Premier Cancer Center Sheba Medical Center Selects Entolimod for Clinical Trial, Potentially Expanding Valion Bio into the Multi-Billion-Dollar Neutropenia Market

Mon, 20 Jul 2026 13:28:00 -0400

Sheba Medical Center, which is ranked the #7 hospital in the world, has chosen to evaluate and fund a trial of Valion Bio's Entolimod in cancer patients, creating a second clinical development pathway beyond Acute Radiation Syndrome.

Highlights

World-Premier Cancer Center Sheba Medical Center Selects Entolimod for Clinical Trial, Potentially Expanding Valion Bio into the Multi-Billion-Dollar Neutropenia Market

Mon, 20 Jul 2026 13:28:00 -0400

Highlights

World-Premier Cancer Center Sheba Medical Center Selects Entolimod for Clinical Trial, Potentially Expanding Valion Bio into the Multi-Billion-Dollar Neutropenia Market

Mon, 20 Jul 2026 13:28:00 -0400

Highlights

World-Premier Cancer Center Sheba Medical Center Selects Entolimod for Clinical Trial, Potentially Expanding Valion Bio into the Multi-Billion-Dollar Neutropenia Market

Mon, 20 Jul 2026 13:28:00 -0400

Highlights

Form DEF 14A Valion Bio, Inc. For: Aug 14

Fri, 17 Jul 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260717/26784750.html

Form DEF 14A Valion Bio, Inc. For: Aug 14

Fri, 17 Jul 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260717/26784750.html

Form S-1 Valion Bio, Inc.

Fri, 17 Jul 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260717/26784282.html

Form S-1 Valion Bio, Inc.

Fri, 17 Jul 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260717/26784282.html

Form SCHEDULE 13G Valion Bio, Inc. Filed by: Murchinson Ltd.

Fri, 17 Jul 2026 10:17:00 -0400

si-local-file:///var/storage/secattach/20260717/26782732.html

Form SCHEDULE 13G Valion Bio, Inc. Filed by: Murchinson Ltd.

Fri, 17 Jul 2026 10:17:00 -0400

si-local-file:///var/storage/secattach/20260717/26782732.html

Valion Bio reports manufacturing scale-up and government talks for Entolimod

Tue, 14 Jul 2026 07:45:44 -0400

Valion Bio, Inc. (Nasdaq: VBIO) announced a series of developments for its Entolimod drug program, including a 200-fold manufacturing scale-up, ongoing discussions with U.S. government agencies and plans to expand into oncology, according to a company press release dated July 14, 2026.

The San Antonio-based biotechnology company said its wholly owned subsidiary, Velocity Bioworks, demonstrated the scale-up at the 50-liter fermentation level, which the company estimates is equivalent to approximately 1.3 million potential human doses, while meeting purity and potency specifications.

Valion Bio said it is continuing talks with the Biomedical Advanced Research and Development Authority, the National Institute of Allergy and

Valion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion

Tue, 14 Jul 2026 07:45:00 -0400

Strategic execution across multiple initiatives positions the Entolimod platform to pursue opportunities in government preparedness, domestic biomanufacturing and oncology supportive care

SAN ANTONIO, July 14, 2026 /PRNewswire/ -- Valion Bio, Inc. (Nasdaq: VBIO) ("Valion Bio" or the "Company") is pleased to report across a series of strategic initiatives for its Entolimod program — including continued engagement with U.S. government agencies and allied nations on Acute Radiation Syndrome (ARS) preparedness, a demonstrated 200-fold manufacturing scale-up through its wholly owned subsidiary Velocity Bioworks®, and planned expansion into innovative

Valion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion

Tue, 14 Jul 2026 07:45:00 -0400

Strategic execution across multiple initiatives positions the Entolimod platform to pursue opportunities in government preparedness, domestic biomanufacturing and oncology supportive care

Valion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion

Tue, 14 Jul 2026 07:45:00 -0400

Strategic execution across multiple initiatives positions the Entolimod platform to pursue opportunities in government preparedness, domestic biomanufacturing and oncology supportive care

Valion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion

Tue, 14 Jul 2026 07:45:00 -0400

Strategic execution across multiple initiatives positions the Entolimod platform to pursue opportunities in government preparedness, domestic biomanufacturing and oncology supportive care

Valion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion

Tue, 14 Jul 2026 07:45:00 -0400

Strategic execution across multiple initiatives positions the Entolimod platform to pursue opportunities in government preparedness, domestic biomanufacturing and oncology supportive care